Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The brokerage currently has a $3.50 price objective on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 10.06% from the stock’s current price.
According to Zacks, “Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom. “
A number of other equities research analysts also recently commented on CNTA. The Goldman Sachs Group cut their price objective on Centessa Pharmaceuticals from $12.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, May 24th. Morgan Stanley decreased their price objective on shares of Centessa Pharmaceuticals from $19.00 to $15.00 and set an “overweight” rating for the company in a report on Tuesday, May 24th. Finally, Jefferies Financial Group cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a report on Friday.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.09. On average, equities analysts anticipate that Centessa Pharmaceuticals will post -2.48 EPS for the current fiscal year.
In related news, EVP Antoine Yver sold 20,222 shares of the company’s stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $5.42, for a total value of $109,603.24. Following the completion of the transaction, the executive vice president now directly owns 813,675 shares of the company’s stock, valued at approximately $4,410,118.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 9.09% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in CNTA. Point72 Asset Management L.P. boosted its position in shares of Centessa Pharmaceuticals by 263.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,097,908 shares of the company’s stock worth $12,362,000 after acquiring an additional 795,708 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in Centessa Pharmaceuticals in the fourth quarter worth $167,000. General Atlantic L.P. grew its holdings in Centessa Pharmaceuticals by 545.5% in the third quarter. General Atlantic L.P. now owns 9,681,818 shares of the company’s stock worth $161,686,000 after purchasing an additional 8,181,818 shares during the period. Boxer Capital LLC grew its holdings in shares of Centessa Pharmaceuticals by 47.6% during the third quarter. Boxer Capital LLC now owns 1,334,227 shares of the company’s stock valued at $22,282,000 after buying an additional 430,000 shares during the last quarter. Finally, RA Capital Management L.P. grew its holdings in shares of Centessa Pharmaceuticals by 179.4% during the third quarter. RA Capital Management L.P. now owns 3,577,094 shares of the company’s stock valued at $59,737,000 after buying an additional 2,296,794 shares during the last quarter. 95.72% of the stock is currently owned by hedge funds and other institutional investors.
About Centessa Pharmaceuticals (Get Rating)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.
- Get a free copy of the StockNews.com research report on Centessa Pharmaceuticals (CNTA)
- CrowdStrike earnings and revenue beat forecasts, stock falls
- Ryder System, Inc: The Most Interesting Play In Logistics
- This Isn’t A Buyable Bottom For Stocks
- Macys Stock is Ready to Buy
- First Solar Stock is Ready to Shine
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.